• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Scorpius Holdings Inc.

    8/6/24 8:53:44 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPX alert in real time by email
    FWP 1 scpx_fwp.htm FREE WRITING PROSPECTUS

    Issuer Free Writing Prospectus

    Pursuant to Rule 433

    Registration No. 333-280887

    August 6, 2024

     

     

    Explanatory Note

     

    This Free Writing Prospectus is being filed to present an updated Capitalization table contained in the Scorpius Holdings, Inc. (the “Company”) registration statement on Form S-1 (File No. 333-280887) (the “Registration Statement”) as a result of the proposed issuance and sale of 12,500,000 shares of common stock (or pre-funded warrants in lieu thereof) at a proposed public offering price of $1.00 per share, which would increase the outstanding share number of the Company to 12,993,268 shares of common stock.

     

    This communication contains information about us and the proposed offering, but it does not contain all of the information that you should consider before investing. The Company has filed the Registration Statement (including a preliminary prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus in the Registration Statement (including the risk factors described therein) and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. The Registration Statement and preliminary prospectus are available on the SEC Web site at www.sec.gov. Alternatively, the Company or any underwriter participating in the offering will arrange to send you the prospectus if you contact ThinkEquity, Prospectus Department, 17 State Street, 41st Floor, New York, New York 10004, telephone (877) 436-3673.

     

    CAPITALIZATION

      

    All historical share and per share information and historical financial information presented below have been adjusted to reflect the 2024 Reverse Stock Split.

     

    The following table sets forth our cash and our capitalization as of March 31, 2024:

     

    ●   on an actual basis;

     

    ●   on a pro forma basis, giving effect to (i) the receipt of $750,000 from the proceeds of the issuance of the New Note and the forgiveness of such New Note, (ii) our issuance of 149,100 shares of common stock, pre-funded warrants to purchase 150,900 shares of common stock and Common Warrants to purchase 300,000 shares of common stock in our offering that closed on May 16, 2024 and the receipt of net proceeds of $5,180,122 from such sale, (iii) our issuance of 6,545 Common Warrants and 6,545 shares of common stock pursuant to exercises of the overallotment option in our offering that closed on May 16, 2024 and our receipt of net proceeds of approximately $121,000 from such sales, (iv) our issuance of 7,434 shares of common stock upon exercise of Common Warrants and our receipt of net proceeds of $178,424 from such exercise, and (v) adjustments made as a result of fractional shares resulting from the 2024 Reverse Stock Split that were eliminated and paid in cash; and

     

    ●   on a pro forma as adjusted basis, giving effect to the pro forma adjustments set forth above and our issuance and sale of 12,500,000 shares of our common stock in this offering based on the public offering price of $1.00 per share, and assuming no exercise of the over-allotment option and no sale of Pre-Funded Warrants, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

    The pro forma as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined at pricing. You should read the information in this table together with our consolidated financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, incorporated by reference in this prospectus. 

       March 31, 2024 
       Actual  

     

    Pro Forma

       Pro Forma As Adjusted 
             
    Cash and cash equivalents  $1,554,844    7,784,390    18,884,388 
                    
    Long-term debt               
    Convertible Note Payable   2,081,750    2,081,750    2,081,750 
                    
    Stockholder’s equity               
    Common stock, $0.0002 par value; 250,000,000 shares authorized, and 180,159 shares issued and outstanding, actual; 250,000,000 shares authorized, and 493,268 shares issued and outstanding, pro forma; 250,000,000 shares authorized, and 12,993,268 shares issued and outstanding, pro forma as adjusted   36    99    2,599 
    Additional paid-in capital   287,258,280    293,487,763(1)   304,585,263 
    Accumulated deficit   (258,788,376)   (258,788,376)   (258,788,376)
    Accumulated other comprehensive income   129,875    129,875    129,875 
    Total Stockholder’s Equity- Scorpius Holdings, Inc.   28,599,815    34,829,361    45,929,361 
    Non-Controlling Interest   (3,342,336)   (3,342,336)   (3,342,336)
    Total Stockholder’s Equity   25,257,479    31,487,025    42,587,025 
    Total Capitalization  $27,339,229    33,568,775   $44,668,773 

     

     

     (1)

    The features of the warrants issued in the May 16, 2024 offering may result in a warrant derivative liability that we would record in our financial statements. Accordingly, a portion of the net proceeds from such sale may be allocated to a derivative warrant liability instead of equity. We have not yet finalized the accounting treatment for the issuance of such warrants and therefore at this time cannot determine the extent of such liability, if any.

     

    The table above is based on 180,159 shares of our common stock outstanding as of March 31, 2024 and gives effect to the pro forma adjustments described above and excludes as March 31, 2024 the following:

     

    ●   30,895 shares of common stock issuable upon exercise of stock options outstanding and expected to vest as of March 31, 2024, at a weighted-average exercise price of $723.46 per share; and
    ●   6,087 shares of our common stock that are available for future issuance under our stock incentive plans or shares that will become available under our stock incentive plans.

     

     

    Get the next $SCPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPX
    SEC Filings

    View All

    Scorpius Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Events That Accelerate or Increase a Direct Financial Obligation

    8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

    1/29/26 4:15:42 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

    1/13/26 4:57:10 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Scorpius Holdings Inc.

    10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)

    1/12/26 4:31:32 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

    5/14/25 8:30:00 AM ET
    $SCPX
    $TIVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

    Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

    5/5/25 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

    SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id

    4/30/25 4:05:30 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Thuan Tan Sze

    3 - Scorpius Holdings, Inc. (0001476963) (Issuer)

    3/12/25 4:07:02 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

    4 - Scorpius Holdings, Inc. (0001476963) (Issuer)

    5/17/24 4:30:21 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Leadership Updates

    Live Leadership Updates

    View All

    Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

    Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

    5/5/25 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

    DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo

    11/14/24 4:15:00 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

    DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu

    10/2/24 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

    9/26/24 4:05:52 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

    9/6/24 4:01:41 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

    SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)

    5/21/24 5:25:39 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care